Wilber W. Su, MD – FDA 483, Feb 27, 2026

Wilber W. Su, MD, a clinical investigator in Phoenix, AZ, was cited for failing to conduct an investigation according to the signed agreement and investigational plan. The inspection revealed issues with enrolling ineligible subjects, incomplete baseline assessments, and a lack of documentation for protocol deviations. These findings indicate significant non-compliance with study protocols.